Amarin (AMRN) Beats on EPS, Misses Revenue

Amarin Corporation plc (AMRN) shares are up $0.07, or 4.55%, to $1.61 in after-hours trading Tuesday after the company reported its fourth quarter earnings results.

The biopharmaceutical firm reported non-GAAP earnings of ($0.11) per share on revenues of $16.48 million, up 63.1% from a year ago. Analysts were expecting EPS of ($0.13) on revenues of $17.08 million. Under GAAP, Amarin reported a net loss of $19.7 million, or $0.11 per share.

For full-year 2014, revenues totaled $54.2 million as compared to $26.4 million in 2013, an increase of 105%.

On valuation measures, Amarin Corp. PLC ADS shares, which currently have an average 3-month trading volume of 1.72 million shares, trade with a P/E to growth ratio of (0.03). The median Wall Street price target on the name is $6.00. Currently ticker boasts 1 ‘Buy’ endorsements, compared to 7 ’Holds’ and no ‘Sell’.

Profitability-wise, AMRN has a t-12 profit and operating margin of (108.97%) and (221.34%), respectively. The $268.87 million market cap company reported $119.5 million in cash vs. $89.61 million in debt in its most recent quarter.

AMRN currently prints a one year loss of 11.49% and a year-to-date return of around 57%.

The chart below shows where the equity has traded over the last 52 weeks.

Amarin Corp. plc, is a biopharmaceutical company focused on the development and commercialization of therapeutic products for the treatment for cardiovascular diseases in the United States. The firm was founded in 1989 and is based in Dublin, Ireland.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.